
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc demonstrated positive financial momentum, recording a 21% increase in top-line growth in Q3, driven by a 13% rise in volume and a 5% increase in average selling prices (ASPs). The company achieved its highest quarterly cash collections in history during October and has expanded its sales force by approximately 50%, positioning itself for further growth in volumes. With consistent year-over-year growth in kidney surveillance volumes and the recent achievement of GAAP net income positivity, CareDx has raised its financial guidance, reflecting a strong outlook for continued performance.
Bears say
CareDx Inc. has reported a year-over-year volume increase of 13% for Q3'25, but the volumes fell short of expectations, indicating potential market challenges and seasonal slowdowns. The stock is currently trading at a significant discount to historical averages, raising concerns about the company's ability to capitalize on growth opportunities amidst ongoing risks associated with management turnover and the commercialization of new diagnostic solutions. Additionally, uncertainties regarding potential changes in Medicare coverage for kidney testing could further complicate CareDx's revenue trajectory and strategic growth initiatives.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares